


ATPase VCP/p97 Inhibitor – NMS-859

Chemical Name: 2-chloro-N-(3-((1,1-dioxidobenzo[d]isothiazol-3-yl)amino)phenyl)acetamide



Molecular Weight:	349.79
Formula:	C ₁₅ H ₁₂ ClN ₃ O ₃ S
Purity:	≥98%
CAS#:	1449236-96-7
Solubility:	DMSO up to 100 mM
Storage	Powder: 4 °C 1 year
	DMSO: 4 °C 3 months
	-20 °C 1 year

Biological Activity:

NMS-859 is a potent and specific small molecule covalent inhibitor of the ATPase VCP/p97 (IC₅₀ ~0.37 μ M), identified by high-throughput screening. It is very selective (IC₅₀ >10 μ M) against all of the AAA ATPases, HSP90 or the 53 kinases tested. NMS-859 was active in a cell proliferation assay, with IC₅₀ values of 3.5 μ M and 3.0 μ M in HCT116 and HeLa cell lines, respectively. NMS-859 covalently modifies VCP on the active site Cys522 and blocks ATP binding. NMS-859 provided critical validation of VCP as a cancer target, and it raises the possibility that targeting VCP might prevent proteasome inhibitor–resistant tumors from escaping through the aggresome-autophagy pathways and cause them to collapse under the high load of unfolded proteins.

How to Use:

In vitro: NMS-859 was used at 2.5-10 µM final concentration in various in vitro assays.

In vivo: n/a

Reference:

1. Magnaghi P, et al. Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death. (2013) Nat Chem Biol. 9(9):548-56

Products are for research use only. Not for human use.